OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Coleman on Benefit of Rucaparib in Ovarian Cancer

March 28th 2019

Robert Coleman, MD, professor in the Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, discusses the benefit of rucaparib in the treatment of patients with ovarian cancer.

Dr. Graziano on Sequencing Targeted Therapy in NSCLC

March 28th 2019

Stephen L. Graziano, MD, professor of medicine, division chief of medicine, and division chief of Upstate Cancer Center Adult Hematology/Oncology at the Upstate University Hospital, discusses sequencing targeted therapy for patients with non–small cell lung cancer (NSCLC).

Dr. Wallen on Technological Advances in NSCLC

March 28th 2019

Jason M. Wallen, MD, MBA, FACS, FCCP, associate professor of surgery, division chief of thoracic surgery, director of gastric and esophageal cancer program, medical director of the thoracic oncology program, Upstate University Hospital, discusses technological advances made in non–small cell lung cancer (NSCLC).

Dr. Tagawa Discusses Darolutamide in CRPC

March 28th 2019

Scott T. Tagawa, MD, Richard A. Stratton Associate Professor in Hematology and Oncology, associate professor of clinical medicine and urology at Weill Cornell Medicine, associate attending physician, NewYork-Presbyterian-Weill Cornell Medical Center, discusses darolutamide in castration-resistant prostate cancer.

Dr. Euhus on the Rarity of Angiosarcoma of the Breast

March 28th 2019

David M. Euhus, MD, director of breast surgery, professor of surgery, Johns Hopkins Medicine, discusses the rarity of angiosarcoma of the breast.

Dr. Somer on Optimal Combinations in mRCC

March 27th 2019

Bradley G. Somer, MD, an associate professor of hematology/oncology and head of strategic expansion/development at the University of Tennessee West Cancer Center, discusses optimal combinations for the treatment of patients with metastatic renal cell carcinoma (mRCC) in the frontline setting.

Dr. Sabari on Managing Immune-Related Adverse Events in Lung Cancer

March 27th 2019

Joshua K. Sabari, MD, assistant professor, Department of Medicine, NYU Langone’s Perlmutter Cancer Center, discusses the management of immune-related adverse events (irAEs) in patients with lung cancer.

Dr. Subramanian on the IMpower131 Trial in Squamous NSCLC

March 27th 2019

Janakiraman Subramanian, MD, medical oncologist, director of Thoracic Oncology, Center for Precision Medicine, Saint Luke’s Cancer Institute, discusses the IMpower131 trial in advanced squamous non–small cell lung cancer (NSCLC).

Dr. Matulonis on Individualized Dosing of Niraparib in Ovarian Cancer

March 26th 2019

Ursula A. Matulonis, MD, director, Gynecologic Oncology, Dana-Farber Cancer Institute, professor of medicine, Harvard Medical School, discusses individualized dosing of niraparib in the treatment of patients with ovarian cancer.

Dr. Higano on Role of PARP Inhibitors in Prostate Cancer

March 26th 2019

Celestia Higano, MD, FACP, member, Clinical Research Division, Fred Hutchinson Cancer Research Center, professor, Department of Medicine and Urology, University of Washington, Seattle Cancer Care Alliance, discusses the role of PARP inhibitors in prostate cancer.

Dr. Hurvitz on Toxicity Associated With Neratinib in HER2+ Breast Cancer

March 26th 2019

Sara A. Hurvitz, MD, director of the Breast Oncology Program, medical director of the Clinical Research Unit, University of California, Los Angeles Jonsson Comprehensive Cancer Center, discusses toxicity associated with neratinib in the treatment of patients with HER2-positive breast cancer.

Dr. Hunt on Treating Local Regional Recurrence in Breast Cancer

March 26th 2019

Kelly Hunt, MD, professor and chair of Breast Surgical Oncology at The University of Texas MD Anderson Cancer Center, discusses treatment approaches for patients with breast cancer who have local regional recurrence.

Dr. Ferguson on a Population-Based Study of Women Undergoing Radical Hysterectomy

March 26th 2019

Sarah Ferguson, MD, FRCSC, associate professor of gynecologic oncology, University of Toronto, Princess Margaret Cancer Centre, discusses a population-based study of women with cervical cancer undergoing radical hysterectomy.

Dr. Bardia on Sacituzumab Govitecan in TNBC

March 26th 2019

Aditya Bardia, MD, MPH, director of Precision Medicine at the Center for Breast Cancer, Massachusetts General Hospital Cancer Center, and assistant professor of medicine, Harvard Medical School, discusses the potential of sacituzumab govitecan in patients with triple-negative breast cancer (TNBC).

Dr. Perez-Soler on Improved Outlook for Patients With Lung Cancer

March 26th 2019

Roman Perez-Soler, MD, chairman of the Department of Oncology and chief of the Division of Medical Oncology at Montefiore Medical Center, discusses the improved outlook for patients with lung cancer.

Dr. Socinski on Mechanisms of Resistance in Lung Cancer

March 26th 2019

Mark A. Socinski, MD, executive medical director, AdventHealth Medical Group, discusses mechanisms of resistance in the treatment of patients with lung cancer.

Dr. Quinn on Targetable Molecular Pathways in RCC

March 26th 2019

David I. Quinn, MBBS, PhD, associate professor of medicine, section head, Genitourinary Oncology, Division of Cancer Medicine and Blood Diseases, USC Keck School of Medicine, discusses targetable molecular pathways in renal cell carcinoma.

Dr. Pegram on Promising Novel Agents in HER2+ Metastatic Breast Cancer

March 22nd 2019

Mark D. Pegram, MD, Susy Yuan-Huey Hung Professor, co-director, Stanford’s Molecular Therapeutics Program, director, Breast Cancer Oncology Program, Stanford Women’s Cancer Center, discusses promising novel agents in the treatment of patients with HER2-positive metastatic breast cancer.

Dr. Sznol on Unanswered Questions With Immunotherapy in RCC

March 22nd 2019

Mario Sznol, MD, professor of medicine, co-director, Yale SPORE in Skin Cancer, Yale Cancer Center, discusses unanswered questions with immunotherapy in the treatment of patients with renal cell carcinoma.

Dr. Slovin Discusses History of Immunotherapy in Prostate Cancer

March 22nd 2019

Susan F. Slovin, MD, PhD, a medical oncologist at Memorial Sloan Kettering Cancer Center, discusses the history of immunotherapy in the treatment of patients with prostate cancer.